ABIVAX

NAME OF THE CEO
Prof. Hartmut Ehrlich, M.D.

ADDRESS
5 rue de la Baume,
75008 Paris

EMAIL
info@abivax.com
www.abivax.com

MANAGEMENT TEAM
CEO: Prof. Hartmut Ehrlich, M.D.
CFO: Didier Blondel
CMO: Jean-Marc Steens, M.D.
CCO & VP BD: Pierre Courteille

MISSION
ABIVAX is a biotechnology company harnessing the immune system to develop a functional cure for HIV and treatments for inflammatory diseases and cancer.

TECHNOLOGY
ABIVAX leverages three technology platforms for drug discovery:
• an antiviral platform
• an immune enhancement platform
• a polyclonal antibody platform

ALLIANCES/PARTNERSHIPS
Partnerships
• CNRS / Curie Institute
Licenses
• Scripps Research Institute

UPCOMING CATALYSTS

REVENUES 2017: 0 €
Date of IPO: June 2015
Ticker: ABVX.PA
Exchange: Euronext Paris
Currency: €
Market cap: 72 million € (as of May 3, 2018)
Price: 7.33 € (as of May 3, 2018)
52-weeks-high: 18.76 €
52-weeks-low: 7 €
Average daily volume: 52000 per day in 2017

KEY FIGURES

<table>
<thead>
<tr>
<th>Key Figure</th>
<th>2016</th>
<th>2017</th>
<th>Growth (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales</td>
<td>0</td>
<td>0</td>
<td>0%</td>
</tr>
<tr>
<td>EBIT</td>
<td>-18</td>
<td>-14</td>
<td>22%</td>
</tr>
<tr>
<td>Net Income</td>
<td>-14</td>
<td>-11</td>
<td>21%</td>
</tr>
<tr>
<td>Cash Position</td>
<td>17</td>
<td>23</td>
<td>-26%</td>
</tr>
</tbody>
</table>

LISTED COMPANY
CREATION DATE
December 2013

TARGETED MARKET
- HIV: Towards a functional cure for HIV: Targeting RNA splicing
- IBD (Ulcerative Colitis & Crohn’s Disease)
- Immuno-oncology in HCC in combination with checkpoint inhibitors
ABIVAX

NAME OF THE CEO
Prof. Hartmut Ehrlich, M.D.

ADDRESS
5 rue de la Baume,
75008 Paris

EMAIL
info@abivax.com
www.abivax.com

MANAGEMENT TEAM
CEO: Prof. Hartmut Ehrlich, M.D.
CFO: Didier Blondel
CMO: Jean-Marc Steens, M.D.
CCO & VP BD: Pierre Courtéille

TARGETED MARKET
• HIV: Towards a functional cure for HIV: Targeting RNA splicing
  • IBD (Ulcerative Colitis & Crohn’s Disease)
  • Immuno-oncology in HCC in combination with checkpoint inhibitors

LISTED COMPANY
CREATION DATE
December 2013

ANALYST COVERAGE

<table>
<thead>
<tr>
<th>Broker</th>
<th>Date</th>
<th>Reco. (buy Neutral/hold)</th>
<th>Target Price</th>
<th>Potential (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NIBC</td>
<td>03/2018</td>
<td>Buy</td>
<td>15,10 €</td>
<td>+106%</td>
</tr>
<tr>
<td>Goetz Partners</td>
<td>10/2017</td>
<td>Buy</td>
<td>19,50 €</td>
<td>+166%</td>
</tr>
<tr>
<td>RBC</td>
<td>05/2017</td>
<td>Buy</td>
<td>26,00 €</td>
<td>+255%</td>
</tr>
<tr>
<td><strong>Average:</strong></td>
<td></td>
<td><strong>Buy</strong></td>
<td><strong>20,2 €</strong></td>
<td><strong>+176%</strong></td>
</tr>
</tbody>
</table>

SHAREHOLDERS

Shareholder structure² (undiluted)

- Public: 35%
- Truffle Capital: 60%
- Incubator Holding: 3%
- Founders: 2%

As of December 31st, 2017

PIPECASE

- Lead generation
- Research
- Preclinical
- Phase 1
- Phase 2
- Phase 3

- HIV: Lasting viral remission
- Ulcerative Colitis: Anti-inflammatory
- Cancer: Immune enhancer
- Ebola: Polyclonal antibodies
- Dengue: Antiviral drug
- Respiratory Syncytial Virus: Antiviral drug
- Influenza: Antiviral drug

ABIVAX has a mature and growing pipeline as of December 31st, 2017.